A Massachusetts start-up launched by a microbiome-therapy business incubator needs approval for an investigational new drug study for research it already started on the effects a medical food ingredient it developed might have on COVID-19 infections.
Kaleido Biosciences Inc., a Flagship Pioneering company, has informed the Food and Drug Administration that “it is developing a procedure...





